<DOC>
	<DOCNO>NCT00985660</DOCNO>
	<brief_summary>The objective study investigate bioequivalence nisoldipine extended-release 30 mg tablet ( Mylan Pharmaceuticals Inc. ) Sular® Extended-Release 30 mg tablet ( manufacture First Horizon ) follow single , oral 30 mg ( 1 × 30 mg tablet ) dose administration healthy adult subject fasting condition .</brief_summary>
	<brief_title>Bioequivalence Study Nisoldipine Extended-Release Tablets , 30 mg</brief_title>
	<detailed_description />
	<mesh_term>Nisoldipine</mesh_term>
	<criteria>Age : 18 year old . Sex : Male and/or nonpregnant , nonlactating female . Women childbearing potential must negative serum beta human chorionic gonadotropin ( βHCG ) pregnancy test perform within 21 day prior start study even prior dose administration . If dose schedule Sunday Monday , HCG pregnancy test give within 48 hour prior dose study period . An additional serum ( βHCG ) pregnancy test perform upon completion study . Women childbearing potential must practice abstinence use acceptable form contraception throughout duration study . No hormonal contraceptive hormonal replacement therapy permit study . Acceptable form contraception include follow : 1 . Intrauterine device place least 3 month prior start study remain place study period , 2 . Barrier method contain use conjunction spermicidal agent , 3 . Surgical sterilization Women consider childbearing potential one follow report documented medical history : 1 . Postmenopausal absence menses least one ( 1 ) year , 2 . Bilateral oophorectomy without hysterectomy absence bleed least 6 month , 3 . Total hysterectomy During course study , study screen study exit include washout period , men woman childbearing potential must use spermicide contain barrier method contraception addition current contraceptive method . This advice document informed consent form . Weight : At least 60 kg ( 132 lb ) men 48 kg ( 106 lb ) woman subject Body Mass Index ( BMI ) less equal 30 great equal 19 . All subject judge normal healthy prestudy medical evaluation ( physical examination , laboratory evaluation , Hepatitis B Hepatitis C test , HIV test , 12lead ECG , urine drug screen include amphetamine , barbiturate , benzodiazepine , cannabinoid , cocaine , opiates , phencyclidine , methadone ) perform within 21 day initial dose study medication Institutionalized subject use . Social Habits : Use tobaccocontaining product within 1 year start study . Ingestion alcoholic , caffeine xanthinecontaining food beverage within 48 hour prior initial dose study medication . Ingestion vitamins herbal product within 7 day prior initial dose study medication . Any recent , significant change dietary exercise habit . A positive test drug include urine drug screen . History drug and/or alcohol abuse . Medications : Use prescription overthecounter ( OTC ) medication within 14 day prior initial dose study medication . Use hormonal contraceptive hormone replacement therapy within 3 month prior study medication dosing . Use medication know alter hepatic enzyme activity within 28 day prior initial dose study medication . Diseases : History significant cardiovascular , hepatic , renal , pulmonary , hematologic , gastrointestinal , endocrine , immunologic , dermatologic , neurologic disease . Acute illness time either prestudy medical evaluation dosing . A positive HIV , hepatitis B , hepatitis C test . Abnormal clinically significant laboratory test result : Clinically significant deviation Guide Clinically Relevant Abnormalities ( See Part II ADMINISTRATIVE ASPECTS OF BIOEQUIVALENCE PROTOCOLS ) . Abnormal clinically relevant ECG tracing . Donation loss significant volume blood plasma ( &gt; 450 mL ) within 28 day prior initial dose study medication . Subjects received investigational drug within 30 day prior initial dose study medication . Allergy hypersensitivity nisoldipine , inactive ingredient , calcium channel blocker product . History difficulty swallow , gastrointestinal disease could affect drug absorption . Consumption grapefruit grapefruit containing product within 7 day drug administration . Average sit pulse rate le 55 beat per minute five minute rest screening OR prior Period I Day 1 dosing . Pulse rate measurement take triplicate least two ( 2 ) minute elapse inbetween measurement . Average sit systolic blood pressure le 90 mmHg average sit diastolic blood pressure le 60 mmHg follow five ( 5 ) minute rest screening OR prior Period I Day 1 dosing . Blood pressure measurement take triplicate least two ( 2 ) minute elapse inbetween reading .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
</DOC>